Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World check: does the CLL drug acalabrutinib live up to trial hype?

NCT ID NCT05437250

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 27, 2026 · Updated 2 times

Summary

This study looks at how well the drug acalabrutinib works for people with chronic lymphocytic leukemia (CLL) when used in regular hospitals, not just in clinical trials. Researchers will track 350 patients in France for about 3 years to see how long they stay on the drug and why they might stop. The goal is to understand real-world benefits and challenges, without giving any new treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

CLL patients

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients aged ≥ 18 years old, * CLL patients initiated with acalabrutinib at their physician's discretion between January 1st 2021 and December 31st 2022, * Patients alive at study initiation and who have been informed verbally and/or in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control (certified by physician); or patient who died before study initiation and who did not object to data collection for research purpose(s) during his or her lifetime. Exclusion Criteria: * Patients participating in a clinical trial with an investigational drug within 30 days prior to acalabrutinib initiation, * Patients who initiated acalabrutinib treatment before January 1st 2021.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphocytic leukemia

Contacts and locations

Locations

  • Research Site

    Aix-en-Provence, France

  • Research Site

    Amiens, France

  • Research Site

    Angers, France

  • Research Site

    Ars-Laquenexy, France

  • Research Site

    Avignon, France

  • Research Site

    Besançon, France

  • Research Site

    Béziers, France

  • Research Site

    Bobigny, France

  • Research Site

    Bourg-en-Bresse, France

  • Research Site

    Brest, France

  • Research Site

    Caen, France

  • Research Site

    Cahors, France

  • Research Site

    Carcassonne, France

  • Research Site

    Cesson-Sévigné, France

  • Research Site

    Chalon-sur-Saône, France

  • Research Site

    Chambéry, France

  • Research Site

    Clamart, France

  • Research Site

    Clermont-Ferrand, France

  • Research Site

    Corbeil-Essonnes, France

  • Research Site

    Dunkirk, France

  • Research Site

    Essey-lès-Nancy, France

  • Research Site

    Grenoble, France

  • Research Site

    La Chaussée-Saint-Victor, France

  • Research Site

    La Tronche, France

  • Research Site

    LE Chesnay-rocquencourt, France

  • Research Site

    Le Kremlin-Bicêtre, France

  • Research Site

    Le Mans, France

  • Research Site

    Le Puy-en-Velay, France

  • Research Site

    Lens, France

  • Research Site

    Libourne, France

  • Research Site

    Lille, France

  • Research Site

    Limoges, France

  • Research Site

    Lorient, France

  • Research Site

    Marseille, France

  • Research Site

    Meaux, France

  • Research Site

    Melun, France

  • Research Site

    Mont-de-Marsan, France

  • Research Site

    Nantes, France

  • Research Site

    Nevers, France

  • Research Site

    Nîmes, France

  • Research Site

    Orléans, France

  • Research Site

    Paris, France

  • Research Site

    Perpignan, France

  • Research Site

    Pessac, France

  • Research Site

    Périgueux, France

  • Research Site

    Pontoise, France

  • Research Site

    Reims, France

  • Research Site

    Rennes, France

  • Research Site

    Roubaix, France

  • Research Site

    Rouen, France

  • Research Site

    Saumur, France

  • Research Site

    Tarbes, France

  • Research Site

    Toulouse, France

  • Research Site

    Tours, France

  • Research Site

    Trévenans, France

  • Research Site

    Troyes, France

  • Research Site

    Valence, France

  • Research Site

    Vandœuvre-lès-Nancy, France

  • Research Site

    Vantoux, France

  • Research Site

    Vesoul, France

  • Research Site

    Vichy, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.